Bluebonnet, which manufactures the majority of its products at its facility in Texas, was founded in 1991. Bluebonnet Nutrition Corp. makes and markets vitamins and other dietary supplements, including amino acids and herbs, under the Bluebonnet brand name. It provides its supplements in multiple forms, such as capsules, soft gels, powders, and liquids. Lead products include Super Earth Phytonutrient Soy Protein Powder and Multi-Action Whey of Life Protein Powder. The family-owned company sells its products in health and natural food stores throughout the US, as well as in Europe and Asia, to retailers that include Whole Foods Market.

BioVest offers cell culture products, instruments, and related contract services to research institutions, biotech firms, and pharmaceutical companies. The company is also developing a therapeutic cancer vaccine for follicular non-Hodgkin's lymphoma that is customized for individual patient use. The candidate, dubbed BiovaxID, is undergoing late-stage clinical trials. Its AutovaxID product is a cell culture instrument designed to ease use of BiovaxID. BioVest is 76% owned by Accentia Biopharmaceuticals. Both BioVest and Accentia filed for Chapter 11 bankruptcy in 2008 and are restructuring their operations.

Lexicon Pharmaceuticals, Inc company was founded in 1995 and is headquartered in The Woodlands, Texas. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which is in a Phase II clinical trial for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX1032 that has completed Phase I clinical trials to treat the symptoms associated with carcinoid syndrome; LX2931, which is in Phase I clinical trial for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX4211 that is in Phase 1 clinical trials to treat Type 2 diabetes. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. Lexicon Pharmaceuticals has drug discovery alliances with Bristol-Myers Squibb Company to discover, develop, and commercialize small molecule drugs in the neuroscience field; and N.V. Organon to discover, develop, and commercialize new biotherapeutic drugs. It also has an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

MY Medicare wants to help with your medical care. Mingyuan Medicare Development, or MY Medicare, makes medical diagnostic products for the Chinese market. Its HealthDigit subsidiary produces biochips that detect certain proteins in the body and are used to diagnose and monitor cancer as well as track treatment efficacy. The company has agreements with major Chinese insurance companies, including Taiping Life, China Life, and Ping An Life, that use the chips in medical checkups. MY Medicare also makes a testing kit used to detect cervical cancer. It offers consultation for clinical and technical research and conducts training and seminars from research centers and plants in Shanghai and Beijing.

Lonza Group stays busy making active ingredients. Spun off by Switzerland's former industrial giant Alusuisse Lonza Group (Algroup), Lonza Group is focused mostly on research and production for pharmaceutical and chemical firms. It is a contract manufacturer of the advanced intermediates and active ingredients used in drugs. Lonza also is active in biotechnology: It uses microbial fermentation and biotransformation to produce fine chemical intermediates and is involved in mammalian cell culture research. It also produces organic fine chemicals and performance chemicals (biocides and oleochemicals).

Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) provides research and development support for the pharmaceutical business units of parent company, Johnson & Johnson. Its main research processes are divided into three franchises: central nervous system and internal medicine; biotech, immunology, and oncology (through J&J subsidiary Centocor); and virology (through Tibotec). The subsidiary -- which represents the largest segment of J&J's pharmaceutical R&D -- also does research in collaboration with other pharmaceutical organizations and biotech researchers, and has partnerships with the likes of Basilea Pharmaceuticals and Entelos.

DiagnoCure Inc. company was founded in 1994 and is headquartered in Quebec City, Canada. DiagnoCure, Inc., a life sciences company, engages in the research, development, production, and commercialization of diagnostic tests for the detection and management of cancers in Canada. It focuses on colon, prostate, breast, and lung cancers. The company provides ImmunoCyt /uCyt+, a tool for the diagnosis and monitoring of bladder cancer; uPM3, a noninvasive test for the detection of prostate cancer; and molecular diagnostic tests for lung cancer. It also offers Previstage GCC colorectal cancer staging test for the management of colorectal cancer. The company holds worldwide diagnostic and therapeutic rights for the use of the PCA3 technology in prostate cancer diagnosis. DiagnoCure has a strategic alliance with Gen-Probe Incorporated for the development and commercialization of diagnostic products using the DiagnoCure PCA3 gene technology for prostate cancer.

Symbollon is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its I2 technology. I2 is the chemical symbol for molecular iodine. Molecular iodine is the active species of iodine, a proven fast acting, broad-spectrum antimicrobial and therapeutic. Formed in 1986, Symbollon completed its initial public offering in December 1993. Since that time we have pursued product applications for our technology in two distinct areas; women’s healthcare and antimicrobial applications.In female health, Symbollon has developed a proprietary oral tablet based on our technology that generates I2 in situ (the stomach of the patient). We refer to this drug as IoGen. In 2000, Symbollon completed Phase I and II clinical trials evaluating IoGen as a potential treatment for fibrocystic breast disease. Phase III pivotal trials will be conducted in 2005. We believe that IoGen may also be useful for the treatment and prevention of other types of excess cell growth in female reproductive tissue, such as endometriosis, ovarian cysts and pre-menopausal breast cancer.

Vivalis SA was founded in 1999 and is headquartered in Saint-Herblain, France. Vivalis SA, a biopharmaceutical company, develops and sells cell-based solutions to the pharmaceutical industry for the manufacture of viral vaccines and therapeutic proteins. Its proprietary technologies include EB66 cell line platform, which is derived from duck embryonic stem cells that presents industrial and regulatory characteristics to replace the eggs in the production of vaccines and to produce antibodies with enhanced antibody dependent cell cytotoxicity activity; and the 3D-SCREEN molecular screening platform that is used to identify and develop molecules for the purpose of blocking the action of proteins involved in major viral pathologies. The company also develops drugs for the prevention and treatment of viral diseases, notably for the treatment of hepatitis C.

The Westaim Corporation was founded in 1996. The Westaim Corporation, a holding company, develops, manufactures and commercializes medical products that fight infection and inflammation. Nucryst Pharmaceuticals Corp. Nucryst develops, manufactures and commercializes innovative medical products that fight infection and inflammation. Wound Care Products: Acticoat Burn Dressings and Acticoat 7 Dressings, targeting the burn and chronic wound markets, were developed and sold by Nucryst. Nucryst's license to Smith & Nephew grants Smith & Nephew the exclusive worldwide right to market, distribute and sell Acticoat products using Nucryst's SILCRYST coatings for use on non-minor dermal wounds or burns in humans, including improvements to those products, and any new products developed with Smith & Nephew using Nucryst's SILCRYST coatings or powders in the Field. There are six product families with SILCRYST coatings manufactured by Nucryst for Smith & Nephew at its Fort Saskatchewan plant: Acticoat Burn, Acticoat 7, Acticoat Absorbent, Acticoat Moisture Control, Acticoat Site, and Acticoat Post-Op. In 2008, Nucryst announced that Health Canada granted marketing approval for a new SILCRYST product, Acticoat Flex Barrier Dressing. Agreements with Smith & Nephew: In 2007, Nucryst signed amended agreements with Smith & Nephew for the manufacture and sale of Acticoat products.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.